Browsing ICR Divisions by author "Chisholm, Julia"
Now showing items 1-20 of 25
-
A systematic review of early phase studies for children and young people with relapsed and refractory rhabdomyosarcoma: The REFoRMS-SR project.
Evans, C; Shepherd, L; Bryan, G; Fulbright, H; Crowther, S; et al. (WILEY, 2024-04-01)Rhabdomyosarcoma is the commonest soft tissue sarcoma in children. Around one-third of children with rhabdomyosarcoma experience relapse or have refractory disease, which is associated with a poor prognosis. This systematic ... -
Access to clinical trials for adolescents with soft tissue sarcomas: Enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols
Ferrari, A; Trama, A; De Paoli, A; Bergeron, C; Merks, JHM; et al. (2017-06) -
Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial.
Bisogno, G; Jenney, M; Bergeron, C; Gallego Melcón, S; Ferrari, A; et al. (ELSEVIER SCIENCE INC, 2018-08-01)BACKGROUND: Rhabdomyosarcoma is an aggressive tumour that can develop in almost any part of the body. Doxorubicin is an effective drug against rhabdomyosarcoma, but its role in combination with an established multidrug ... -
Adolescents and young adults with rhabdomyosarcoma treated in the European paediatric Soft tissue sarcoma Study Group (EpSSG) protocols: a cohort study.
Ferrari, A; Chisholm, JC; Jenney, M; Minard-Colin, V; Orbach, D; et al. (Elsevier BV, 2022-06-08)BACKGROUND: Adolescent and young adult patients with rhabdomyosarcoma often have poorer outcomes than do children. We aimed to compare the findings of adolescent and young adult patients with children enrolled in two ... -
BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma.
Chisholm, JC; Suvada, J; Dunkel, IJ; Casanova, M; Zhang, W; et al. (WILEY, 2018-05-01)BACKGROUND: Vemurafenib, a selective inhibitor of BRAF kinase, is approved for the treatment of adult stage IIIc/IV BRAF V600 mutation-positive melanoma. We conducted a phase I, open-label, dose-escalation study in pediatric ... -
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors
Doz, F; van Tilburg, CM; Geoerger, B; Højgaard, M; Øra, I; et al.Abstract Background Larotrectinib is a first-in-class, highly selective tropomyosin receptor kinase (TRK) inhibitor approved to treat adult and pediatric patients with TRK fusion-positive cancer. The aim of this study was ... -
Evidence of Chemoresponsiveness in Unresectable Metastatic Angiomatoid Fibrous Histiocytoma.
Corley, EA; Pace, E; Barnacle, AM; Patel, PA; Thway, K; et al. (Ovid Technologies (Wolters Kluwer Health), 2023-01-16)Angiomatoid fibrous histiocytoma (AFH) is a soft tissue neoplasm of intermediate biological potential. Typically a slow-growing tumor, it can recur locally. Rarely, it manifests as a soft tissue sarcoma capable of metastasis. ... -
Immune reconstitution in children following chemotherapy for acute leukemia.
Williams, AP; Bate, J; Brooks, R; Chisholm, J; Clarke, SC; et al. (WILEY, 2020-07-01)Although survival rates for pediatric acute lymphoblastic leukemia are now excellent, this is at the expense of prolonged chemotherapy regimens. We report the long-term immune effects in children treated according to the ... -
Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? The European experience.
Vaarwerk, B; Mallebranche, C; Affinita, MC; van der Lee, JH; Ferrari, A; et al.Background After the completion of therapy, patients with localized rhabdomyosarcoma (RMS) are subjected to intensive radiological tumor surveillance. However, the clinical benefit of this surveillance is unclear. This ... -
Local staging and treatment in extremity rhabdomyosarcoma. A report from the EpSSG-RMS2005 study.
Terwisscha van Scheltinga, SEJ; Wijnen, MHWA; Martelli, H; Rogers, T; Mandeville, H; et al.Rhabdomyosarcoma of the extremities present with two main challenges: correct evaluation of initial regional nodal involvement and define adequate local treatment. Methods Pediatric patients with localized rhabdomyosarcoma ... -
Maintenance Chemotherapy for Patients with Rhabdomyosarcoma.
Bisogno, G; Minard-Colin, V; Jenney, M; Ferrari, A; Chisholm, J; et al. (MDPI, 2023-08-07)Maintenance chemotherapy (MC) defines the administration of prolonged relatively low-intensity chemotherapy with the aim of "maintaining" tumor complete remission. This paper aims to report an update of the RMS2005 trial, ... -
Outcomes in lung-only metastatic rhabdomyosarcoma: an analysis of data from the European paediatric Soft tissue sarcoma Study Group MTS 2008 study
Chisholm, JC; Schoot, RA; Cameron, AL; Casanova, M; Minard-Colin, V; et al. (Elsevier BV, 2023-06-01) -
Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.
Moreno, L; Casanova, M; Chisholm, JC; Berlanga, P; Chastagner, PB; et al. (2018-09)Background nab-Paclitaxel has demonstrated efficacy in adults with solid tumours and preclinical activity in paediatric solid tumour models. Results from phase I of a phase I/II study in paediatric patients with ... -
Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
Defachelles, A-S; Bogart, E; Casanova, M; Merks, JHM; Bisogno, G; et al.Purpose The VIT-0910 trial was conducted to evaluate efficacy and safety of the vincristine-irinotecan combination with and without temozolomide (VIT and VI, respectively) in relapsed or refractory rhabdomyosarcoma (RMS). ... -
Rhabdomyosarcoma with unknown primary tumor site: A report from European pediatric Soft tissue sarcoma Study Group (EpSSG).
Affinita, MC; Merks, JHM; Chisholm, JC; Haouy, S; Rome, A; et al. (WILEY, 2022-11-01)BACKGROUND: Rhabdomyosarcoma (RMS) is an aggressive malignancy, and 20% of children present with metastases at diagnosis. Patients presenting with disseminated disease very occasionally have no clear evidence of a primary ...